New drug duo takes on tough rectal cancer
NCT ID NCT06933251
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding two drugs—a PCSK9 inhibitor and a PD-1 inhibitor—to standard chemoradiotherapy can help shrink tumors in patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS). The study involves 30 participants and aims to see how well the treatment works and how safe it is. The approach is experimental and still in early stages.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PCSK9 inhibitor and PD-1 inhibitor combined with chemoradiotherapy
What this could lead to
If successful, this could offer a new treatment option for patients with a hard-to-treat form of rectal cancer, potentially improving tumor response and organ preservation.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou
Guangzhou, Guangdong, China